Jana Partners LLC reduced its stake in shares of Radius Health, Inc. (NASDAQ:RDUS) by 1.9% during the first quarter, Holdings Channel reports. The firm owned 168,992 shares of the biopharmaceutical company’s stock after selling 3,318 shares during the period. Jana Partners LLC’s holdings in Radius Health were worth $6,532,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Creative Planning boosted its stake in shares of Radius Health by 11.5% in the first quarter. Creative Planning now owns 16,685 shares of the biopharmaceutical company’s stock valued at $645,000 after buying an additional 1,720 shares in the last quarter. DUPONT CAPITAL MANAGEMENT Corp purchased a new stake in shares of Radius Health during the first quarter valued at $304,000. Russell Investments Group Ltd. purchased a new stake in shares of Radius Health during the fourth quarter valued at $197,000. Guggenheim Capital LLC boosted its stake in shares of Radius Health by 3.9% in the fourth quarter. Guggenheim Capital LLC now owns 65,355 shares of the biopharmaceutical company’s stock valued at $2,485,000 after buying an additional 2,453 shares in the last quarter. Finally, Artal Group S.A. boosted its stake in shares of Radius Health by 100.0% in the fourth quarter. Artal Group S.A. now owns 100,000 shares of the biopharmaceutical company’s stock valued at $3,803,000 after buying an additional 50,000 shares in the last quarter.
Shares of Radius Health, Inc. (RDUS) traded up 0.72% during midday trading on Friday, hitting $40.83. The company’s stock had a trading volume of 798,286 shares. Radius Health, Inc. has a 12-month low of $31.58 and a 12-month high of $59.88. The firm’s market cap is $1.77 billion. The firm has a 50-day moving average of $36.65 and a 200 day moving average of $40.55.
Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.18) by $0.14. During the same quarter in the previous year, the firm posted ($0.94) earnings per share. On average, equities research analysts predict that Radius Health, Inc. will post ($4.42) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was first published by sleekmoney and is the property of of sleekmoney. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://sleekmoney.com/radius-health-inc-rdus-shares-sold-by-jana-partners-llc/1916333.html.
Several equities research analysts have weighed in on the company. Maxim Group set a $24.00 target price on Radius Health and gave the stock a “sell” rating in a report on Saturday, March 11th. J P Morgan Chase & Co reiterated a “buy” rating on shares of Radius Health in a report on Saturday, March 11th. Canaccord Genuity set a $85.00 target price on Radius Health and gave the stock a “buy” rating in a report on Saturday, March 11th. Cantor Fitzgerald set a $65.00 target price on Radius Health and gave the stock a “buy” rating in a report on Saturday, February 25th. Finally, Jefferies Group LLC lowered their target price on Radius Health from $40.00 to $34.00 and set a “hold” rating for the company in a report on Tuesday, May 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $56.83.
In related news, major shareholder Growth N. V. Biotech bought 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 18th. The stock was purchased at an average cost of $34.41 per share, for a total transaction of $1,720,500.00. Following the completion of the acquisition, the insider now owns 4,958,799 shares in the company, valued at approximately $170,632,273.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Growth N. V. Biotech bought 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was bought at an average price of $36.25 per share, with a total value of $1,450,000.00. Following the completion of the acquisition, the insider now owns 4,998,799 shares of the company’s stock, valued at approximately $181,206,463.75. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 548,400 shares of company stock valued at $19,202,788. 15.00% of the stock is currently owned by company insiders.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, abaloparatide for subcutaneous injection, or abaloparatide-SC, has completed Phase III development for potential use in the treatment of women with postmenopausal osteoporosis.
Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health, Inc. (NASDAQ:RDUS).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/radius-health-inc-rdus-shares-sold-by-jana-partners-llc/1916333.html
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.